Welcome to our dedicated page for XOMA Royalty news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty stock.
XOMA Royalty Corporation operates as a biotechnology royalty aggregator that acquires rights to potential milestone and royalty payments tied to therapeutic candidates licensed to pharmaceutical and biotechnology companies. Its updates commonly address portfolio additions, royalty-sharing transactions, commercial and development-stage assets, clinical and regulatory disclosures from underlying programs, and cash receipts from royalties and milestones.
Company news also covers financial results, preferred stock dividends on its Series A and Series B cumulative preferred securities, completed acquisitions that expand the royalty portfolio, and executive or governance changes. Named portfolio assets include VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, DARE to PLAY, DSUVIA, and development-stage assets such as mezagitamab.
XOMA Royalty (NASDAQ:XOMA) has announced its subsidiary XRA 5 Corp. will acquire Mural Oncology (NASDAQ:MURA) in an all-cash transaction valued at approximately $36.2 million. Under the agreement, Mural shareholders will receive a base price of $2.035 per share, with potential for an additional $0.205 per share based on Mural's closing net cash position.
The base offer represents a 13.1% premium to Mural's closing price of $1.80 on August 19, 2025, and a 97.6% premium to its undisturbed price of $1.03 on April 14, 2025. The acquisition, recommended by Mural's board, follows a strategic review process and is expected to close by the end of 2025, subject to shareholder and regulatory approvals.
XOMA Royalty (NASDAQ:XOMA) reported Q2 2025 financial results and significant business developments. The company received $29.6 million in royalties and milestones in H1 2025, including $11.7 million in Q2. Notable achievements include the acquisition of multiple companies (Turnstone Biologics, LAVA Therapeutics, and HilleVax) and the $20 million purchase of mezagitamab royalty rights from BioInvent.
Q2 2025 financial highlights include net income of $9.2 million and total income/revenue of $13.1 million. The company ended Q2 with $78.5 million in cash and cash equivalents. Several pipeline advancements were reported, including Rezolute's completion of Phase 3 enrollment for ersodetug and EMA's acceptance of Day One's tovorafenib MAA.
[ "Received $29.6 million in royalties and milestones in H1 2025", "Net income of $9.2 million in Q2 2025, up from $7.4 million in Q2 2024", "Strategic acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax expanding portfolio", "Strong cash position of $78.5 million as of June 30, 2025", "Multiple pipeline advancements including regulatory milestones and Phase 3 trial progress", "Decreased G&A expenses to $7.8 million in Q2 2025 from $11.0 million in Q2 2024" ]XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire Turnstone Biologics (NASDAQ: TSBX). The deal terms included $0.34 per share in cash plus one non-tradeable contingent value right (CVR).
As of the expiration date on August 7, 2025, 17,192,002 shares were validly tendered, representing approximately 74% of Turnstone's outstanding shares. Following the tender offer, XOMA Royalty merged Turnstone with its subsidiary XRA 3 Corp., making Turnstone a wholly owned subsidiary. Turnstone's shares will cease trading on Nasdaq as of August 11, 2025, and will be delisted and deregistered.
XOMA Royalty (NASDAQ: XOMA) has entered into a definitive agreement to acquire LAVA Therapeutics (NASDAQ: LVTX) in a structured deal valued at $1.16 to $1.24 per share in cash, plus a contingent value right (CVR). The CVR entitles shareholders to 75% of net proceeds from LAVA's partnered assets and potential out-licensing of unpartnered programs.
The transaction, expected to close in Q4 2025, requires at least 80% shareholder tender and includes specific closing conditions. As part of the deal, LAVA will discontinue its Phase 1 clinical trial of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome. The acquisition adds milestone and royalty economics from LAVA's gamma delta bispecific antibodies portfolio to XOMA Royalty's assets.
XOMA Royalty (NASDAQ: XOMA) has entered into a definitive merger agreement to acquire HilleVax (NASDAQ: HLVX) in a deal that values HilleVax shares at $1.95 in cash per share plus a contingent value right (CVR).
The CVR includes potential additional payments from: (1) excess cash above $102.95 million, (2) 90-100% of savings from Boston office lease obligations, and (3) 90% of proceeds from any norovirus vaccine program sales within specific timeframes. The deal has secured support from 22.9% of HilleVax stockholders, including officers and directors.
XOMA Royalty will commence a tender offer by August 18, 2025, with the acquisition expected to close in September 2025. The deal requires a majority of HilleVax shares to be tendered and maintaining a minimum cash balance at closing.
ESSA Pharma (NASDAQ: EPIX) has announced a definitive agreement to be acquired by XenoTherapeutics, with financing from XOMA Royalty Corporation (NASDAQ: XOMA). The all-cash transaction will provide EPIX shareholders with approximately $1.91 per common share, plus one non-transferable contingent value right (CVR) worth up to $0.06 per share payable within 18 months post-closing.
The transaction, expected to close in second half of 2025, requires approval from 66⅔% of ESSA shareholders and securityholders. The agreement includes a $2.5 million termination fee and customary deal-protection provisions. ESSA's board unanimously approved the transaction, with directors and senior officers, holding 2.23% of shares, agreeing to vote in favor.
[ "All-cash transaction providing immediate liquidity to shareholders", "Additional potential value through CVR of up to $0.06 per share", "Expedited cash distribution process compared to standard liquidation", "Unanimous board approval and management support with 2.23% commitment" ]XOMA Royalty (NASDAQ:XOMA) has announced a definitive merger agreement to acquire Turnstone Biologics (NASDAQ-CM:TSBX). Under the terms of the agreement, XOMA will pay $0.34 in cash per share plus one non-transferable contingent value right (CVR) for each Turnstone share.
The acquisition will proceed through a tender offer starting by July 11, 2025, requiring a majority of outstanding shares to be tendered and meeting certain conditions including minimum cash balance requirements. Approximately 25.2% of Turnstone stockholders have already agreed to tender their shares. The merger is expected to close in August 2025.
XOMA Royalty Corporation (NASDAQ: XOMA) has acquired BioInvent International's future royalty and milestone rights for mezagitamab (TAK-079) in a deal worth up to $30 million. The transaction includes $20 million paid at closing and an additional $10 million contingent upon mezagitamab receiving FDA marketing approval for IgA nephropathy.
With this acquisition and its existing entitlements, XOMA will receive up to $16.25 million in milestones from Takeda and mid-single digit royalties on future mezagitamab commercial sales. Takeda is currently conducting a Phase 3 clinical trial for mezagitamab in immune thrombocytopenia (ITP) patients. The drug is a fully human IgG1 monoclonal antibody targeting CD38-expressing cells, with potential to become best-in-class in its category.